Abstract | OBJECTIVE: BACKGROUND: METHODS: Ninety-eight patients >1 year to <30 years of age, with slow spike-and-wave patterns on EEG, seizure types including drop attacks, and either a history of or active atypical absence seizures, were assigned to an 11-week, double-blind treatment phase with either topiramate or placebo. Topiramate was titrated to target doses of approximately 6 mg/kg/d. RESULTS: For drop attacks, the most severe seizures associated with this syndrome, the median percentage reduction from baseline in average monthly seizure rate was 14.8% for the topiramate group and -5.1% (an increase) for the placebo group (p = 0.041). Topiramate-treated patients demonstrated greater improvement in seizure severity than did placebo-treated patients based on parental global evaluations (p = 0.037). The percentage of patients with a > or = 50% reduction from baseline in major seizures ( drop attacks and tonic-clonic seizures) was greater in the topiramate group (15/46 or 33%) than in the control group (4/50 or 8%; p = 0.002). The most common adverse events in both groups were CNS related; there were no discontinuations from topiramate therapy due to adverse events. CONCLUSIONS:
|
Authors | R C Sachdeo, T A Glauser, F Ritter, R Reife, P Lim, G Pledger |
Journal | Neurology
(Neurology)
Vol. 52
Issue 9
Pg. 1882-7
(Jun 10 1999)
ISSN: 0028-3878 [Print] United States |
PMID | 10371538
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Anticonvulsants
- Topiramate
- Fructose
|
Topics |
- Adolescent
- Anticonvulsants
(adverse effects, therapeutic use)
- Child
- Child, Preschool
- Double-Blind Method
- Epilepsy
(drug therapy)
- Female
- Fructose
(adverse effects, analogs & derivatives, therapeutic use)
- Humans
- Male
- Topiramate
|